A randomized, double-blind, multiple-dose, placebo-controlled clinical study to investigate efficacy and safety of 4-week treatment with 24 mg daily of the human GATA-3-specific DNAzyme solution for inhalation (SB010) in patients with Type 2-driven asthma inadequately controlled with at least medium-dose inhaled corticosteroids and long-acting beta-agonists on biomarkers (GIANT-1)

To evaluate the effect of once-daily oral inhalation of 1,2 ml SB010 containing 24mg human GATA-3-specific DNAzyme (hgd40), compared to placebo, on airway inflammation in patients with moderate to severe type 2 dominant asthma inadequately controlled on current medium-to-high dose inhaled corticosteroids (ICS) with long-acting β2-agonist (LABA) therapy (Global Initiative for Asthma [GINA 2020] treatment step 4 or 5).